About bk health Modern medical Clinic is a full admission, family-oriented medical practice, open since 2003. We strive to be a leader in providing primary and preventive health care in the Mandurah region. Our company is based on the principles of respect, compassion, service and friendship.
The state-of-the-art medical clinic has attracted a team of highly skilled doctors, nurses and visiting specialists, all dedicated to providing you with quality care. Regular medical examinations and physical examinations play an important role in the early diagnosis and treatment of health problems. Let us help you feel better while having fun with your loved ones.
Top 8 medical innovation for 2022 Revealed
Next-generation anti-mRNA drugs. A new approach to the treatment of prostate cancer. A new drug to lower LDL. These are three of the game-changing technologies that will change health in 2022, according to a panel of Cleveland Clinic doctors and researchers of D. Geoffrey Vince, PhD, Director of Innovations and President of Biomedical Engineering.
“At Cleveland Clinic, a shared passion for providing high-quality care and an integrated culture of innovation fosters an ongoing conversation about improving health among our physicians and researchers,” said Dr. . Vince says. “Therefore, our experts are always looking for new technologies that will change the face of health. The Top 10 Medical Innovations program was created to share their knowledge in all areas of health, and every year, our experts attend further predicting advances in devices, technology and treatments. .
Here, in expected order of importance, are the top 8 health innovations for 2022:
- A new generation of anti-mRNA drugs. Advances in the generation, purification, and cell delivery of RNA have enabled the development of RNA therapeutics in many different applications, such as cancer and the Zika virus. The technology is inexpensive and relatively easy to develop. In addition, the COVID-19 pandemic has shown that the world needs the rapid development of vaccines that can be quickly transported around the world. Thanks to previous research that laid the foundation for this technology, an effective COVID-19 vaccine was developed, developed, approved and delivered in less than a year. Technology is changing the landscape and has the potential to accelerate and eliminate some of the most serious health problems.
- . Targeted therapy for PSMA. Each year, more than 200,000 Americans are diagnosed with prostate cancer, the most common cancer diagnosed in American men. Early detection and successful imaging are important for tumor staging, staging, and detecting recurrence. Prostate-specific membrane antigen (PSMA), found in high levels on the surface of prostate cancer cells, is a risk factor for the disease. PSMA PET uses a radioactive agent to detect and attach to PSMA proteins, making them visible on PET images. This technique can be used in conjunction with CT scans or MRI to see where prostate cancer cells live. In 2020, this technology received FDA approval based on a Phase 3 trial that showed an increase in accuracy in detecting metastases of prostate cancer compared to bone and bone imaging. CT scan.
- New treatment for lowering LDL. High blood cholesterol, especially low-density lipoprotein (LDL-C), contributes significantly to heart disease. In 2019, the FDA reviewed the application for inclisiran for the treatment of primary hyperlipidemia (including hereditary hypercholesterolemia) in adults with high LDL-C levels while receiving high-dose statins. Inclisiran is a chemically engineered small RNA inhibitor that targets the PCSK9 protein. Unlike statins, it requires frequent administration (twice a year) and provides effective and permanent LDL-C reduction in combination with statins. Its long-term effects can help reduce drug tolerance, one of the main causes of failure to reduce LDL-C levels. Inclisiran was approved by the FDA in December 2021 and is considered a game changer for heart patients.
- . New drugs for the treatment of type 2 diabetes. In the United States, one in ten people suffer from diabetes. One possible treatment is a once-weekly injection of glucose-dependent insulinotropic polypeptide (GIP) and a glucagon-like peptide (GLP-1) agonist that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and inhibit the hormone glucagon, preventing the increase in blood sugar after a meal. In addition, it slows digestion, helping people to sit longer and eat less. The latest 3 trials reveal that the treatment significantly lowers hemoglobin A1C in type 2 diabetes and promotes weight loss, potentially making it the best treatment for diabetes and obesity to date.
- . Advances in treatment for postpartum depression. Experts believe that the prevalence of postpartum depression may be at least twice as high as current statistics show, since many cases go undiagnosed. Counseling and antidepressants are the first treatment, but some women do not respond to these treatments. In 2019, the FDA approved intravenous infusion therapy specifically for postpartum depression. This new treatment, given around the clock for up to 60 hours, uses neurosteroids to control the brain’s response to stress. This treatment is revolutionary because it focuses on showing the idea that it is the deficiency and depression of the hormone that responds after childbirth. Also, this treatment seems to show benefits quickly, while traditional antidepressants usually take two to four weeks to have a significant effect. This quick treatment option will be a breakthrough for women with this often overlooked condition.
- Targeted drug for hypertrophic cardiomyopathy. For decades, doctors have treated the symptoms of hypertrophic cardiomyopathy (HCM) in patients with little effectiveness. Non-specific medications are given to treat some of the symptoms HCM shares with other heart diseases. These medications include beta blockers, antiarrhythmics, calcium channel blockers, and blood thinners. However, new treatments are working to reduce the causes of HCM in many patients. First-class drugs target the heart muscle to reduce abnormal clotting caused by a variety of genetic factors that put the heart into overdrive. By acting specifically on this process in HCM patients, this new treatment not only improves symptoms and quality of life, but can actually slow down the disease. The FDA has assigned a target date of April 28, 2022 for this treatment. If approved, it will be the first drug dedicated to the treatment of HCM, giving patients and doctors new hope.
- Other non-hormonal options for treating menopausal hot flashes. More than 50% of postmenopausal women suffer from hot flashes, which can last for an average of seven years. Hormone therapy is effective and safe when used properly, but it comes with some risks. Also, not all patients are in need of hormone therapy. Fortunately, a new class of non-hormonal drugs, called NK3R antagonists, has emerged as an alternative to hormone therapy. These drugs disrupt the signaling pathways in the brain that are involved in the development of inflammation. They have shown promise in clinical trials for relieving mild and severe menopausal hot flashes like hormones. Although more studies are needed to fully understand the efficacy and safety of these new drugs, it is clear that the next generation of non-hormonal treatments for menopausal hot flashes is on the horizon. machine.
- It can be implanted for severe paralysis. About 1 in 50 Americans, or 5.4 million people, has some form of paralysis. Although the cost of treatment is high, its benefits are not compared to the negative effects of patients. Many patients with paralysis experience significant declines in their overall health. Recently, a group gave these patients new hope by using brain-computer implanted technology to regain lost motor control and allow patients to control digital devices. The technology uses implanted electrodes to collect movement signals from the brain and record them into movement commands. It has also been shown to restore voluntary motor stimulation in patients with severe paralysis due to dysfunction of the brain, intestines, nerves or muscles. Although the interface technology is still in its infancy, the FDA has designated the implant as a “developmental device,” making it necessary to move this new technology to the bedside of patients who need it.